Prostate cancer organoids pave way towards precision oncology

Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.

Researchers at the Georgia Institute of Technology, US, have developed research tools that shed new light on a currently untreatable form of prostate cancer, opening a pathway that may lead to novel therapeutics.

Read the full article here.

Source: Anne Begley - Drug Target Review